Form 4: Vor Biopharma Inc. Officer Attar Eyal C. Reports Stock Sale

Chief Medical Officer Attar Eyal C. of Vor Biopharma Inc. reports selling 2,227 shares of common stock at $1.42 per share on February 13, 2025, under a pre-arranged trading plan.

Summary

• On February 13, 2025, Eyal C. Attar, the Chief Medical Officer of Vor Biopharma Inc., sold 2,227 shares of common stock.
• The sale was executed at a price of $1.42 per share.
• Following the transaction, Attar directly owns 126,625 shares of Vor Biopharma Inc.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on March 4, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was conducted under a pre-arranged trading plan and doesn't necessarily reflect a change in the officer's view of the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It provides transparency into the transactions of company executives and their holdings in the company's stock. Investors often monitor these filings to gain insights into management's perspective on the company's valuation and future prospects.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the small volume of shares sold.

Key Dates